Are you over 18 and want to see adult content?
5
More Annotations
![A complete backup of abil-industrie.fr](https://www.archivebay.com/archive2/97b189e4-9d6c-4ffa-b3c2-1e7ad44f6577.png)
A complete backup of abil-industrie.fr
abil-industrie.fr
Are you over 18 and want to see adult content?
4
![A complete backup of marathonrally.com](https://www.archivebay.com/archive2/45787e50-ebe2-4078-9304-a3f85f98adf4.png)
A complete backup of marathonrally.com
marathonrally.com
Are you over 18 and want to see adult content?
![A complete backup of kura-corpo.co.jp](https://www.archivebay.com/archive2/108ad390-b5cc-4240-a985-67cccbc340e2.png)
A complete backup of kura-corpo.co.jp
kura-corpo.co.jp
Are you over 18 and want to see adult content?
![A complete backup of earthopensource.org](https://www.archivebay.com/archive2/2704c11e-0e5b-4f1f-8528-72d3adeca7d4.png)
A complete backup of earthopensource.org
earthopensource.org
Are you over 18 and want to see adult content?
5
Favourite Annotations
2
3
Text
HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OUR
TEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility FT516 - FATE THERAPEUTICS FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targetingantibodies.
FT538 - FATE THERAPEUTICS FT538. Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multipleapproved
DR. SHEFALI AGARWAL
Dr. Shefali Agarwal is Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical FATE THERAPEUTICS ANNOUNCES WORLDWIDE COLLABORATION WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS ANNOUNCES FIRST SUBJECT TREATED WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS INITIATES PHASE 2 PROTECT STUDY OF The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. MANAGER, REGULATORY AFFAIRS (CMC) JOB CODE 481LL DESCRIPTION Manager, Regulatory Affairs (CMC) Job Code 481LL Description Fate Therapeutics is seeking an experienced and highly motivated regulatoryprofessional to
HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OURTEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility FT516 - FATE THERAPEUTICS FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targetingantibodies.
FT538 - FATE THERAPEUTICS FT538. Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multipleapproved
DR. SHEFALI AGARWAL
Dr. Shefali Agarwal is Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical FATE THERAPEUTICS ANNOUNCES WORLDWIDE COLLABORATION WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS ANNOUNCES FIRST SUBJECT TREATED WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS INITIATES PHASE 2 PROTECT STUDY OF The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. MANAGER, REGULATORY AFFAIRS (CMC) JOB CODE 481LL DESCRIPTION Manager, Regulatory Affairs (CMC) Job Code 481LL Description Fate Therapeutics is seeking an experienced and highly motivated regulatoryprofessional to
INVESTORS | FATE THERAPEUTICS, INC. Investors. Corporate Profile. We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate thetherapeutic
FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 531ED, SENIOR DIRECTOR, GLOBAL MARKETING Job Code 531ED Description Fate Therapeutics is seeking an experienced Senior Director of Global Marketing to provide broad early commercial and global marketing leadership across our pipeline of iPSC-derived, off-the-shelf NK and T cell therapies. This role will support early program development and Disease Area teams to shape clinical development strategies within oncology and ensure FATE THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN FIRST SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in the Company’s first-in-human Phase 1 clinical trial evaluating FT596, the first cell therapy FT596 - FATE THERAPEUTICS FT596 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which hasbeen
0000899243-21-022085 The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. SENIOR DIRECTOR, GLOBAL MARKETING JOB CODE 531ED Senior Director, Global Marketing . Job Code 531ED . Description . Fate Therapeutics is seeking an experienced Senior Director of Global Marketing to provide ROBERT S. EPSTEIN, M.D. Robert S. Epstein, M.D. Dr. Epstein is an epidemiologist and strategic consultant to life sciences companies and serves on the board of directors of Illumina, Inc., Veracyte, Inc., a molecular diagnostic company, Proteus Digital Health, Inc., a healthcare technology company, and Decipher Biosciences, a urologic cancer diagnosticscompany.
FATE THERAPEUTICS ANNOUNCES ENCOURAGING DOSE-ESCALATION The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FATE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF KARIN JOOSS SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Karin Jooss, Ph.D. has been appointed to the Company’s Board of Directors.Dr. Jooss has more than 20 years of experience in HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OURTEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility INVESTORS | FATE THERAPEUTICS, INC. Investors. Corporate Profile. We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate thetherapeutic
PIPELINE - FATE THERAPEUTICS Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited. Program Cell TypeFunctionality Target(s) Indication(sJOIN OUR TEAM
Fate Therapeutics is seeking a highly-motivated, skilled, and conscientious individual to join the analytical development team to support the development of off-the-shelf pluripotent cell-derived NK and T cell cancer immunotherapies. The successful candidate will participate in novel assay development, qualification, and implementation of flowIPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 FT596 - FATE THERAPEUTICS FT596 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which hasbeen
EVENTS & PRESENTATIONS The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FT538 - FATE THERAPEUTICS FT538. Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multipleapproved
HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OURTEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility INVESTORS | FATE THERAPEUTICS, INC. Investors. Corporate Profile. We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate thetherapeutic
PIPELINE - FATE THERAPEUTICS Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited. Program Cell TypeFunctionality Target(s) Indication(sJOIN OUR TEAM
Fate Therapeutics is seeking a highly-motivated, skilled, and conscientious individual to join the analytical development team to support the development of off-the-shelf pluripotent cell-derived NK and T cell cancer immunotherapies. The successful candidate will participate in novel assay development, qualification, and implementation of flowIPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 FT596 - FATE THERAPEUTICS FT596 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which hasbeen
EVENTS & PRESENTATIONS The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FT538 - FATE THERAPEUTICS FT538. Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multipleapproved
OUR MISSION
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To produce better cell therapies, we use human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to createPUBLICATIONS
FT500 J Clin Invest. 2018; 128(10): 4654–4668. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade British Journal of Cancer. 2018; 118: 9–16. Mechanisms of resistance to immune checkpoint inhibitors Nature Communications. 2017; 8: 1136. Resistance to checkpoint blockade therapy through inactivation of antigen presentation FT516 Blood. 2020; 135 (6): 399–410 CONTACT - FATE THERAPEUTICS Fate Therapeutics, Inc. 3535 General Atomics Court, Suite 200 San Diego, CA 92121 Coming from the North 5 South to Genesee > Exit Right on Genesee > Right on John J Hopkins Dr > Right on General Atomics Ct. Fate is the first building on the right Coming from the South 5 Northto Genesee
IPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell MANAGEMENT - FATE THERAPEUTICS Management. Fate’s management team has the passion and experience to explore new biology, develop innovative therapeutics, create formidable intellectual property, launch new business models and foster high-value strategic collaborations. Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and isresponsible for the
FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 CGMP MASS PRODUCTION OF FT538, A FIRST-OF-KIND, OFF-THE Page - 3 - FT538 is an Investigational, Off-the-shelf, Multiplexed Engineered Natural Killer (NK) Cell Cancer Immunotherapy •FT538 NK cells are derived from a clonal master induced pluripotent stem cell 0000899243-21-022085 The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.DR. SHEFALI AGARWAL
Dr. Shefali Agarwal is Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical FATE THERAPEUTICS ANNOUNCES WORLDWIDE COLLABORATION WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OURTEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility INVESTORS | FATE THERAPEUTICS, INC. Investors. Corporate Profile. We are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate thetherapeutic
PIPELINE - FATE THERAPEUTICS Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited. Program Cell TypeFunctionality Target(s) Indication(sJOIN OUR TEAM
Fate Therapeutics is seeking a highly-motivated, skilled, and conscientious individual to join the analytical development team to support the development of off-the-shelf pluripotent cell-derived NK and T cell cancer immunotherapies. The successful candidate will participate in novel assay development, qualification, and implementation of flowIPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 FT596 - FATE THERAPEUTICS FT596 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which hasbeen
EVENTS & PRESENTATIONS The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FT538 - FATE THERAPEUTICS FT538. Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multipleapproved
HOME - FATE THERAPEUTICSABOUT USPIPELINESCIENCECOLLABORATIONSJOIN OURTEAMINVESTORS
©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGALMANUFACTURING
GMP Production In September 2019, we opened our cGMP compliant manufacturing facility for the clinical production of our iPSC-derived cell product candidates. Our cGMP facility, located in San Diego, California, is custom designed for the manufacture of off-the-shelf cell product candidates using clonal master iPSC lines as the starting cell source. The new state-of-the-art facility INVESTORS | FATE THERAPEUTICS, INC. The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. PIPELINE - FATE THERAPEUTICS Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited. Program Cell TypeFunctionality Target(s) Indication(sJOIN OUR TEAM
Job Code 515SM Description. Fate Therapeutics is seeking a highly-motivated, skilled, and conscientious individual to join the analytical development team to support the development of off-the-shelf pluripotent cell-derived NK and T cell cancerimmunotherapies.
IPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 FT596 - FATE THERAPEUTICS T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master EVENTS & PRESENTATIONS The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. FT538 - FATE THERAPEUTICS Multiple myeloma is a hematologic malignancy characterized by the proliferation of malignant plasma cells. In multiple myeloma, malignant plasma cells accumulate in the bone marrow and produce abnormal antibodies called M proteins, which can cause kidney damage, bone destruction, and impaired immune function. While multiple approved drugs with novel mechanisms have improved diseaseOUR MISSION
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To produce better cell therapies, we use human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to create CONTACT - FATE THERAPEUTICS Fate Therapeutics, Inc. 3535 General Atomics Court, Suite 200 San Diego, CA 92121 Coming from the North 5 South to Genesee > Exit Right on Genesee > Right on John J Hopkins Dr > Right on General Atomics Ct. Fate is the first building on the right Coming from the South 5 Northto Genesee
PUBLICATIONS
FT500 J Clin Invest. 2018; 128(10): 4654–4668. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade British Journal of Cancer. 2018; 118: 9–16. Mechanisms of resistance to immune checkpoint inhibitors Nature Communications. 2017; 8: 1136. Resistance to checkpoint blockade therapy through inactivation of antigen presentation FT516 Blood. 2020; 135 (6): 399–410IPSC PLATFORM
A Pluripotent Cell Platform for Enabling an Off-the-Shelf Engineered Immunotherapy Revolution Induced pluripotent stem cell (iPSC) technology has the potential to enable the next frontier in the development of cellular therapies. The advent of iPSCs, with their capacity to be genetically engineered and indefinitely expanded in culture, has served to create a potentially unlimited cell FATE THERAPEUTICS ANNOUNCES RETIREMENT OF CHIEF SCIENTIFIC SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that Daniel D. Shoemaker, Ph.D., Chief Scientific Officer, has advised the Company that he is retiring as of June 30, 2021 after more than 12 MANAGEMENT - FATE THERAPEUTICS Fate’s management team has the passion and experience to explore new biology, develop innovative therapeutics, create formidable intellectual property, launch new business models and foster high-value strategic collaborations. CGMP MASS PRODUCTION OF FT538, A FIRST-OF-KIND, OFF-THE Page - 3 - FT538 is an Investigational, Off-the-shelf, Multiplexed Engineered Natural Killer (NK) Cell Cancer Immunotherapy •FT538 NK cells are derived from a clonal master induced pluripotent stem cell 0000899243-21-022085 The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.DR. SHEFALI AGARWAL
Dr. Shefali Agarwal is Chief Medical Officer at Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies for cancer and other serious diseases, where she leads the global clinical development and regulatory strategy for tazemetostat for the treatment of cancer. Prior to joining Epizyme in 2018, Dr. Agarwal held leadership positions across medical research, clinical FATE THERAPEUTICS ANNOUNCES WORLDWIDE COLLABORATION WITH The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.Fate Therapeutics
Primary Menu Skip to content* About Us
* Our Mission
* Our Cells of Interest* Management
* Board of Directors* Pipeline
* Overview
* Immuno-Oncology Candidates* FT500
* FT516
* FT536
* FT596
* FT538
* FT573
* FT576
* FT819
* Early/Expanded Access Policy* Science
* iPSC Platform
* Manufacturing
* Publications
* Collaborations
* Join Our Team
* Vision, Mission, Values* Working at Fate
* Career Opportunities* Investors
* Overview
* Press Releases
* Events & Presentations * Financials & Filings* SEC Filings
* Annual Reports and Proxies * Corporate Governance* Stock Information
* Historical Stock Lookup* Investors FAQs
* Contact
ONE CELL. MANYÂ FATES. TRANSFORMING THE LIVES OF PATIENTS WITH CANCER AND IMMUNE DISORDERS* FT500
* FT516
* FT596
* FT538
* FT576
* FT819
* FT573
* Press Releases
©2021Â Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL* About Us
* Our Mission
* Our Cells of Interest* Management
* Board of Directors* Pipeline
* Overview
* Immuno-Oncology Candidates* FT500
* FT516
* FT536
* FT596
* FT538
* FT573
* FT576
* FT819
* Early/Expanded Access Policy* Science
* iPSC Platform
* Manufacturing
* Publications
* Collaborations
* Join Our Team
* Vision, Mission, Values* Working at Fate
* Career Opportunities* Investors
* Overview
* Press Releases
* Events & Presentations * Financials & Filings* SEC Filings
* Annual Reports and Proxies * Corporate Governance* Stock Information
* Historical Stock Lookup* Investors FAQs
* Contact
Details
3
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0